The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Delcath Systems Inc.
University of Miami
European Institute of Oncology
Spanish Breast Cancer Research Group
SOLTI Breast Cancer Research Group
Dana-Farber Cancer Institute
Seoul National University Hospital
Fudan University
UNICANCER
Novartis
Pierre Fabre Medicament
ETOP IBCSG Partners Foundation
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
National Cancer Institute, Slovakia
ARCAGY/ GINECO GROUP
National Cancer Institute, Naples
US Oncology Research
Second Affiliated Hospital of Soochow University
Sun Yat-sen University
Fudan University
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Shandong Cancer Hospital and Institute
Fudan University
Swiss Cancer Institute
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Medstar Health Research Institute
Fudan University
Fudan University
Shandong Cancer Hospital and Institute
ChineseAMS
ChineseAMS
Spanish Breast Cancer Research Group
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
UNC Lineberger Comprehensive Cancer Center
University of Washington
AIO-Studien-gGmbH
University of Washington
UNC Lineberger Comprehensive Cancer Center
Novartis
Rutgers, The State University of New Jersey
Alliance for Clinical Trials in Oncology
Cancer Research Group - Collaborative Group, Beirut, Lebanon.
Hoffmann-La Roche
University of Aarhus
Alliance for Clinical Trials in Oncology
SCRI Development Innovations, LLC
University Hospital of Crete
Shandong Cancer Hospital and Institute